Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 364

1.

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial.

Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP, Chakravarti A.

JAMA Oncol. 2018 Jun 28. doi: 10.1001/jamaoncol.2018.1977. [Epub ahead of print]

PMID:
29955793
2.

Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care.

Djuric U, Zadeh G, Aldape K, Diamandis P.

NPJ Precis Oncol. 2017 Jun 19;1(1):22. doi: 10.1038/s41698-017-0022-1. eCollection 2017. No abstract available.

3.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 May 31;173(6):1549. doi: 10.1016/j.cell.2018.05.033. Epub 2018 May 31. No abstract available.

PMID:
29856958
4.

A gene expression signature predicts recurrence-free survival in meningioma.

Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP.

Oncotarget. 2018 Feb 15;9(22):16087-16098. doi: 10.18632/oncotarget.24498. eCollection 2018 Mar 23.

5.

The multiforme of glioblastoma.

Nassiri F, Aldape K, Zadeh G.

Neuro Oncol. 2018 Mar 27;20(4):437-438. doi: 10.1093/neuonc/noy025. No abstract available.

PMID:
29596671
6.

DNA methylation-based classification of central nervous system tumours.

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, Garvalov BK, Coras R, Hölsken A, Hewer E, Bewerunge-Hudler M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Staszewski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rushing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Brück W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Hans V, Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner F, Koch A, Jouvet A, Keohane C, Mühleisen H, Mueller W, Pohl U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, Kramm CM, Müller HL, Rutkowski S, von Hoff K, Frühwald MC, Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger G, Wesseling P, Weller M, Collins VP, Blümcke I, Bendszus M, Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Platten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, Acker T, Hartmann C, Aldape K, Schüller U, Buslei R, Lichter P, Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl M, Brandner S, Korshunov A, von Deimling A, Pfister SM.

Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.

PMID:
29539639
7.

A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.

Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, Qin L, Garancher A, Liu KW, Mansouri S, Luu B, Thompson YY, Ramaswamy V, Peacock J, Farooq H, Skowron P, Shih DJH, Li A, Ensan S, Robbins CS, Cybulsky M, Mitra S, Ma Y, Moore R, Mungall A, Cho YJ, Weiss WA, Chan JA, Hawkins CE, Massimino M, Jabado N, Zapotocky M, Sumerauer D, Bouffet E, Dirks P, Tabori U, Sorensen PHB, Brastianos PK, Aldape K, Jones SJM, Marra MA, Woodgett JR, Wechsler-Reya RJ, Fults DW, Taylor MD.

Cell. 2018 Feb 22;172(5):1050-1062.e14. doi: 10.1016/j.cell.2018.01.038. Erratum in: Cell. 2018 May 31;173(6):1549.

PMID:
29474906
8.

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma.

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, Prabhu SS, Rao G, Fuller GN, Aldape KD, Gumin J, Vence LM, Wistuba I, Rodriguez-Canales J, Villalobos PA, Dirven CMF, Tejada S, Valle RD, Alonso MM, Ewald B, Peterkin JJ, Tufaro F, Fueyo J.

J Clin Oncol. 2018 May 10;36(14):1419-1427. doi: 10.1200/JCO.2017.75.8219. Epub 2018 Feb 12.

PMID:
29432077
9.

5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.

Glowacka WK, Jain H, Okura M, Maimaitiming A, Mamatjan Y, Nejad R, Farooq H, Taylor MD, Aldape K, Kongkham P.

Acta Neuropathol. 2018 Apr;135(4):617-634. doi: 10.1007/s00401-018-1821-3. Epub 2018 Feb 10.

10.

EGFR-Induced and PKCε Monoubiquitylation-Dependent NF-κB Activation Upregulates PKM2 Expression and Promotes Tumorigenesis.

Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, Li Y, Verma IM, Chiao PJ, Lu Z.

Mol Cell. 2018 Jan 18;69(2):347. doi: 10.1016/j.molcel.2017.12.034. No abstract available.

11.

A change at the helm of Neuro-Oncology.

Aldape K.

Neuro Oncol. 2018 Jan 10;20(1):1. doi: 10.1093/neuonc/nox229. No abstract available.

PMID:
29329454
12.

Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.

Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, Wang X, Erkek S, Federation A, Song A, Lee C, Wang X, McDonald L, Morrow JJ, Saiakhova A, Sin-Chan P, Wu Q, Michaelraj KA, Miller TE, Hubert CG, Ryzhova M, Garzia L, Donovan L, Dombrowski S, Factor DC, Luu B, Valentim CLL, Gimple RC, Morton A, Kim L, Prager BC, Lee JJY, Wu X, Zuccaro J, Thompson Y, Holgado BL, Reimand J, Ke SQ, Tropper A, Lai S, Vijayarajah S, Doan S, Mahadev V, Miñan AF, Gröbner SN, Lienhard M, Zapatka M, Huang Z, Aldape KD, Carcaboso AM, Houghton PJ, Keir ST, Milde T, Witt H, Li Y, Li CJ, Bian XW, Jones DTW, Scott I, Singh SK, Huang A, Dirks PB, Bouffet E, Bradner JE, Ramaswamy V, Jabado N, Rutka JT, Northcott PA, Lupien M, Lichter P, Korshunov A, Scacheri PC, Pfister SM, Kool M, Taylor MD, Rich JN.

Nature. 2018 Jan 4;553(7686):101-105. doi: 10.1038/nature25169. Epub 2017 Dec 20.

13.

Glut3 Addiction: A Druggable Vulnerability in Glioblastoma.

Bunda S, Zadeh G, Aldape KD.

Cancer Cell. 2017 Dec 11;32(6):726-727. doi: 10.1016/j.ccell.2017.11.017.

PMID:
29232550
14.

IDH mutation testing in gliomas-where do we draw the line?

Nassiri F, Zadeh G, Aldape K.

Neuro Oncol. 2017 Nov 29;19(12):1568-1569. doi: 10.1093/neuonc/nox164. No abstract available.

PMID:
29140514
15.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

PMID:
28988377
16.

Corrigendum: Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.

Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z.

Nature. 2017 Sep 20;550(7674):142. doi: 10.1038/nature24008.

PMID:
28953868
17.

Molecular Signatures for Tumor Classification: An Analysis of The Cancer Genome Atlas Data.

Mamatjan Y, Agnihotri S, Goldenberg A, Tonge P, Mansouri S, Zadeh G, Aldape K.

J Mol Diagn. 2017 Nov;19(6):881-891. doi: 10.1016/j.jmoldx.2017.07.008. Epub 2017 Sep 1.

PMID:
28867603
18.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8.

19.

Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas.

Agnihotri S, Suppiah S, Tonge PD, Jalali S, Danesh A, Bruce JP, Mamatjan Y, Klironomos G, Gonen L, Au K, Mansouri S, Karimi S, Sahm F, von Deimling A, Taylor MD, Laperriere NJ, Pugh TJ, Aldape KD, Zadeh G.

Nat Commun. 2017 Aug 4;8(1):186. doi: 10.1038/s41467-017-00174-7.

20.

Insights From Molecular Profiling of Adult Glioma.

Diamandis P, Aldape KD.

J Clin Oncol. 2017 Jul 20;35(21):2386-2393. doi: 10.1200/JCO.2017.73.9516. Epub 2017 Jun 22. Review.

PMID:
28640696
21.

Gli1-induced deubiquitinase USP48 aids glioblastoma tumorigenesis by stabilizing Gli1.

Zhou A, Lin K, Zhang S, Ma L, Xue J, Morris SA, Aldape KD, Huang S.

EMBO Rep. 2017 Aug;18(8):1318-1330. doi: 10.15252/embr.201643124. Epub 2017 Jun 16.

PMID:
28623188
22.

Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma.

Karimi S, Vyas MV, Gonen L, Tabasinejad R, Ostrom QT, Barnholtz-Sloan J, Suppiah S, Zadeh G, Aldape K.

Neuro Oncol. 2017 Oct 19;19(11):1503-1510. doi: 10.1093/neuonc/nox089.

PMID:
28531342
23.

Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature.

Sahm F, Toprak UH, Hübschmann D, Kleinheinz K, Buchhalter I, Sill M, Stichel D, Schick M, Bewerunge-Hudler M, Schrimpf D, Zadeh G, Aldape K, Herold-Mende C, Beck K, Staszewski O, Prinz M, Harosh CB, Eils R, Sturm D, Jones DTW, Pfister SM, Paulus W, Ram Z, Schlesner M, Grossman R, von Deimling A.

Acta Neuropathol. 2017 Jul;134(1):155-158. doi: 10.1007/s00401-017-1715-9. Epub 2017 May 4. No abstract available.

PMID:
28474103
24.

Atypical meningioma-is it time to standardize surgical sampling techniques?

Jenkinson MD, Santarius T, Zadeh G, Aldape KD.

Neuro Oncol. 2017 Mar 1;19(3):453-454. doi: 10.1093/neuonc/now245. No abstract available.

25.

A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S.

Neuro Oncol. 2017 May 1;19(5):614-624. doi: 10.1093/neuonc/now277. Review.

26.

Proceedings of the WFNS Neuro-Oncology Committee Workshop Rome 2015.

Au K, Ram Z, Zadeh G, Aldape K, Balogun J, Barani I, DiMeco F, Goel A, Khu K, Lang FF, Lund-Johansen M, Maldaun M, Tabatabai G, Tonn JC, Westphal M.

Surg Neurol Int. 2016 Dec 12;7(Suppl 40):S963-S975. doi: 10.4103/2152-7806.195563. eCollection 2016. No abstract available.

27.

Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.

Olar A, Wani KM, Wilson CD, Zadeh G, DeMonte F, Jones DT, Pfister SM, Sulman EP, Aldape KD.

Acta Neuropathol. 2017 Mar;133(3):431-444. doi: 10.1007/s00401-017-1678-x. Epub 2017 Jan 27.

28.

Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.

Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra R.

Oncotarget. 2017 Feb 14;8(7):10845-10857. doi: 10.18632/oncotarget.14802.

29.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

30.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

31.

cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Gregory Cairncross J, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A.

Brain Pathol. 2017 Nov;27(6):851-852. doi: 10.1111/bpa.12457. Epub 2016 Dec 20. No abstract available.

PMID:
27997995
32.

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.

Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236.

33.

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy.

Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor TT, Cairncross JG, Pfister SM, Rutkowski S, Weller M, Wick W, von Deimling A.

Acta Neuropathol. 2017 Jan;133(1):1-3. doi: 10.1007/s00401-016-1646-x. No abstract available.

34.

The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.

Pajtler KW, Mack SC, Ramaswamy V, Smith CA, Witt H, Smith A, Hansford JR, von Hoff K, Wright KD, Hwang E, Frappaz D, Kanemura Y, Massimino M, Faure-Conter C, Modena P, Tabori U, Warren KE, Holland EC, Ichimura K, Giangaspero F, Castel D, von Deimling A, Kool M, Dirks PB, Grundy RG, Foreman NK, Gajjar A, Korshunov A, Finlay J, Gilbertson RJ, Ellison DW, Aldape KD, Merchant TE, Bouffet E, Pfister SM, Taylor MD.

Acta Neuropathol. 2017 Jan;133(1):5-12. doi: 10.1007/s00401-016-1643-0. Epub 2016 Nov 17.

35.

Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.

Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taccone MS, Mansouri S, Golbourn B, Aldape KD, Zadeh G.

Oncotarget. 2016 Oct 25;7(43):69518-69535. doi: 10.18632/oncotarget.11680.

36.

The genomic landscape of schwannoma.

Agnihotri S, Jalali S, Wilson MR, Danesh A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y, Landon-Brace N, Tung T, Dowar M, Li T, Bruce JP, Burrell KE, Tonge PD, Alamsahebpour A, Krischek B, Agarwalla PK, Bi WL, Dunn IF, Beroukhim R, Fehlings MG, Bril V, Pagnotta SM, Iavarone A, Pugh TJ, Aldape KD, Zadeh G.

Nat Genet. 2016 Nov;48(11):1339-1348. doi: 10.1038/ng.3688. Epub 2016 Oct 10.

PMID:
27723760
37.

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.

Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M.

J Neurooncol. 2017 Jan;131(1):193-199. doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.

38.

Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.

Aldape K, Nejad R, Louis DN, Zadeh G.

Neuro Oncol. 2017 Mar 1;19(3):336-344. doi: 10.1093/neuonc/now181.

39.

Identification of Causal Genetic Drivers of Human Disease through Systems-Level Analysis of Regulatory Networks.

Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, Iyer A, Diefes KL, Aldape K, Berens M, Shen MM, Califano A.

Cell. 2016 Aug 11;166(4):1055. doi: 10.1016/j.cell.2016.07.036. No abstract available.

40.

Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.

Zhou A, Lin K, Zhang S, Chen Y, Zhang N, Xue J, Wang Z, Aldape KD, Xie K, Woodgett JR, Huang S.

Nat Cell Biol. 2016 Sep;18(9):954-966. doi: 10.1038/ncb3396. Epub 2016 Aug 8.

41.

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.

Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B.

J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.

42.

DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma.

Mansouri S, Singh S, Alamsahebpour A, Burrell K, Li M, Karabork M, Ekinci C, Koch E, Solaroglu I, Chang JT, Wouters B, Aldape K, Zadeh G.

Oncotarget. 2016 Aug 30;7(35):56431-56446. doi: 10.18632/oncotarget.10570.

43.

Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome.

Johann PD, Hovestadt V, Thomas C, Jeibmann A, Heß K, Bens S, Oyen F, Hawkins C, Pierson CR, Aldape K, Kim SP, Widing E, Sumerauer D, Hauser P, van Landeghem F, Ryzhova M, Korshunov A, Capper D, Jones DTW, Pfister SM, Schneppenheim R, Siebert R, Paulus W, Frühwald MC, Kool M, Hasselblatt M.

Brain Pathol. 2017 Jul;27(4):411-418. doi: 10.1111/bpa.12413. Epub 2016 Aug 11.

PMID:
27380723
44.

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.

Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF.

J Neurooncol. 2016 Aug;129(1):147-54. doi: 10.1007/s11060-016-2157-2. Epub 2016 Jun 7.

45.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis.

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veelen ML, Van Meir EG, Osuka S, Fan X, Muraszko KM, Tirapelli DP, Oba-Shinjo SM, Marie SK, Carlotti CG, Lee JY, Rao AA, Giannini C, Faria CC, Nunes S, Mora J, Hamilton RL, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian RP, Olson JM, Leonard JR, Gardner C, Grajkowska WA, Chambless LB, Cain J, Eberhart CG, Ahsan S, Massimino M, Giangaspero F, Buttarelli FR, Packer RJ, Emery L, Yong WH, Soto H, Liau LM, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis MA, Zagzag D, Wheeler H, von Hoff K, Alonso MM, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan JA, Guzman M, Elbabaa SK, Colman H, Dhall G, Fisher PG, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro AM, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins CE, Rutka JT, Dirks P, Pfister SM, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Ellison DW, Taylor MD.

J Clin Oncol. 2016 Jul 20;34(21):2468-77. doi: 10.1200/JCO.2015.65.7825. Epub 2016 Jun 6.

46.

PIK3CA mutations in meningioma.

Zadeh G, Karimi S, Aldape KD.

Neuro Oncol. 2016 May;18(5):603-4. doi: 10.1093/neuonc/now029. No abstract available.

47.

Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine.

Chang SM, Cahill DP, Aldape KD, Mehta MP.

Am Soc Clin Oncol Educ Book. 2016;35:75-81. doi: 10.14694/EDBK_158869. Review.

48.

Sox2: regulation of expression and contribution to brain tumors.

Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, Zadeh G.

CNS Oncol. 2016 Jul;5(3):159-73. doi: 10.2217/cns-2016-0001. Epub 2016 May 27. Review.

49.

Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH Jr, Dickinson PJ, Fan TM, Corps K, Aldape K, Puduvalli V, Pluhar GE, Gilbert MR.

Neuro Oncol. 2016 Sep;18(9):1209-18. doi: 10.1093/neuonc/now051. Epub 2016 May 14. Review.

50.

Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.

Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen H.

Am J Clin Pathol. 2016 Feb;145(2):222-37. doi: 10.1093/ajcp/aqv023. Epub 2016 Feb 12.

PMID:
27124905

Supplemental Content

Loading ...
Support Center